Curtin University has appointed leading international expert Professor Michael Berndt as the new Pro Vice-Chancellor of the Faculty of Health Sciences.
Professor Berndt joins Curtin from his most recent post as Director of the Biomedical Diagnostics Institute at Dublin City University, and as Professor of Experimental Medicine at the Royal College of Surgeons in Ireland.
Professor Berndt is best known for his research in the areas of thrombosis, inflammation, vascular biology and biomedical diagnostics.
Curtin Vice-Chancellor Professor Jeanette Hacket said Professor Berndt would be a great asset to the dynamic faculty of health sciences.
“I am very pleased to welcome Professor Berndt to Curtin,” Professor Hacket said.
“His high calibre research record and distinguished career in both the commercial and academic areas of health science will bring great new knowledge to the University community.”
Prior to assuming his most recent position at Dublin City University, Professor Berndt was Head of the College of Medicine and Health and the Interim Director of the Biosciences Institute at University College Cork in Ireland.
He has received numerous national and international research awards, including the Glaxo Wellcome Medal in 1996 and a Distinguished Career Award from the International Society on Thrombosis and Haemostasis in 2003. He serves on several editorial boards including the journals, Blood and Journal of Thrombosis and Haemostasis.
He has published more than 290 papers, including in major international journals such as Science, Journal of Experimental Medicine and Blood.
Professor Berndt has collaborated with several pharmaceutical companies and has filed a number of patents, including one licensed to Genetics Institute (Pfizer). He was a co-founder of the ASX-listed proteomics-based biotechnology company, Cryptome Pharmaceuticals Ltd (now Healthlinx).
He is currently Chair of the Executive Council of the International Society on Thrombosis and Haemostasis.
